This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
5 Stocks in the Dow ETF That Survived the Worst Week Since October
by Sweta Killa
Dow Jones witnesses its biggest weekly drop since October amid renewed concerns about economic growth. Let's look at the stocks that survived.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
The Zacks Analyst Blog Highlights AbbVie, Amgen, Stryker, Dexcom and Medtronic
by Zacks Equity Research
AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?
by Kinjel Shah
Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
LLY Rises More Than 4% in a Week: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
by Zacks Equity Research
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
by Zacks Equity Research
Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.
Company News for Feb 6, 2025
by Zacks Equity Research
Companies In The News Are:AMGN, PRU, ATO, SPG.
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
by Zacks Equity Research
REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
by Zacks Equity Research
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.57% and 2.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
by Zacks Equity Research
Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.
Markets React to Softening Trade Tariff Policy
by Mark Vickery
An almost immediate retraction of a 25% tariff on imported goods from Mexico prodded this relief trade.
Dow Logs Best January Since 2019: 5 Best Stocks in the ETF
by Sweta Killa
Dow Jones emerges stronger than the other indices, logging the best January since 2019. Let's look at the five stocks that drove the rally.